Bluebird Bio's Skysona Continues to Benefit Patients Years Later, but Some Develop Blood Cancer
Premium
Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases resolved after treatment.
USC Team Counts Circulating Tumor Cells to Predict Treatment Response, Survival in Prostate Cancer
Premium
The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.
Carrick Therapeutics Advances Second CDK Inhibitor Into Clinic, Explores Biomarker Approaches
Premium
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US and German health authorities.
The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research validates findings from this small study.